MET Exon 14 Skipping Mutations in Lung Cancer: Clinical–Pathological Characteristics and Immune Microenvironment
MET exon 14 skipping mutations have emerged as significant driver alterations in non-small-cell lung cancer (NSCLC), contributing to tumor progression. This study examines the immune microenvironment in NSCLC patients with these mutations and its prognostic implications. We performed multiplex immun...
Saved in:
Main Authors: | Qianqian Xue, Yue Wang, Qiang Zheng, Ziling Huang, Yicong Lin, Yan Jin, Yuan Li |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-07-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/32/7/403 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful Tepotinib Treatment in MET Exon 14 Skipping Mutation‐Positive Lung Adenocarcinoma With Idiopathic Pulmonary Fibrosis Through Nintedanib Combination
by: Yoshiki Kato, et al.
Published: (2025-06-01) -
The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer Identified by Next-Generation Sequencing
by: Jia Liao, MD, et al.
Published: (2025-07-01) -
Possibility of exon skipping therapy for Duchenne muscular dystrophy in Russian patients: present and future
by: E. V. Zinina, et al.
Published: (2024-09-01) -
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy
by: Wuyuan Liao, et al.
Published: (2025-07-01) -
Molecular Genetic Analysis of a DMD Frameshift Mutation in a Boy with Duchenne Muscular Dystrophy by MLPA and Sanger Sequencing
by: Chen Q, et al.
Published: (2025-06-01)